Teleflex Q3 revenue up 19.4% on Vascular acquisition boost, cuts FY forecast

Teleflex Incorporated

06/11/2025 11:38

Overview

Teleflex Q3 GAAP revenue up 19.4% yr/yr, adjusted revenue up 16.8%

Adjusted EPS for Q3 rises to $3.67, despite GAAP EPS loss

Company narrows full-year revenue growth guidance, lowers EPS outlook

Outlook

Teleflex narrows 2025 GAAP revenue growth outlook to 9.10% to 9.60%

Company lowers 2025 adjusted constant currency revenue growth to 6.90% to 7.40%

Teleflex decreases 2025 GAAP EPS outlook to $(4.42) to $(4.22)

Progress in separating into RemainCo and NewCo, with potential sale of NewCo as a focus

Result Drivers

VASCULAR INTERVENTION - Revenue from acquired Vascular Intervention business exceeded guidance, aiding overall revenue growth

INTRA-AORTIC BALLOON PUMPS - Lower-than-expected order rates impacted revenue, particularly in the U.S.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted EPS continuing operations
$3.67
Q3 EPS continuing operations
-$9.24


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 12 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Teleflex Inc is $135.00, about 7.6% above its November 5 closing price of $124.75

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nGNXbbTNBy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)